JP2013519683A5 - - Google Patents

Download PDF

Info

Publication number
JP2013519683A5
JP2013519683A5 JP2012553046A JP2012553046A JP2013519683A5 JP 2013519683 A5 JP2013519683 A5 JP 2013519683A5 JP 2012553046 A JP2012553046 A JP 2012553046A JP 2012553046 A JP2012553046 A JP 2012553046A JP 2013519683 A5 JP2013519683 A5 JP 2013519683A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
treatment
pharmaceutically acceptable
composition according
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012553046A
Other languages
English (en)
Japanese (ja)
Other versions
JP5928828B2 (ja
JP2013519683A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/024583 external-priority patent/WO2011100585A1/en
Publication of JP2013519683A publication Critical patent/JP2013519683A/ja
Publication of JP2013519683A5 publication Critical patent/JP2013519683A5/ja
Application granted granted Critical
Publication of JP5928828B2 publication Critical patent/JP5928828B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012553046A 2010-02-11 2011-02-11 Ｎｍｄａ受容体モジュレータを安定化させる二次構造及びその使用 Active JP5928828B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30347210P 2010-02-11 2010-02-11
US61/303,472 2010-02-11
PCT/US2011/024583 WO2011100585A1 (en) 2010-02-11 2011-02-11 Secondary structure stabilized nmda receptor modulators and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016080043A Division JP6328169B2 (ja) 2010-02-11 2016-04-13 Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物

Publications (3)

Publication Number Publication Date
JP2013519683A JP2013519683A (ja) 2013-05-30
JP2013519683A5 true JP2013519683A5 (enExample) 2014-03-27
JP5928828B2 JP5928828B2 (ja) 2016-06-01

Family

ID=44368160

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012553046A Active JP5928828B2 (ja) 2010-02-11 2011-02-11 Ｎｍｄａ受容体モジュレータを安定化させる二次構造及びその使用
JP2016080043A Expired - Fee Related JP6328169B2 (ja) 2010-02-11 2016-04-13 Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物
JP2018079295A Withdrawn JP2018119004A (ja) 2010-02-11 2018-04-17 Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物
JP2020046041A Pending JP2020117510A (ja) 2010-02-11 2020-03-17 Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016080043A Expired - Fee Related JP6328169B2 (ja) 2010-02-11 2016-04-13 Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物
JP2018079295A Withdrawn JP2018119004A (ja) 2010-02-11 2018-04-17 Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物
JP2020046041A Pending JP2020117510A (ja) 2010-02-11 2020-03-17 Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物

Country Status (13)

Country Link
US (2) US9101612B2 (enExample)
EP (1) EP2542254B1 (enExample)
JP (4) JP5928828B2 (enExample)
CN (2) CN105037492A (enExample)
AU (1) AU2011215704B2 (enExample)
BR (1) BR112012020142A2 (enExample)
CA (1) CA2789331C (enExample)
ES (1) ES2706063T3 (enExample)
IL (1) IL221400A (enExample)
MX (1) MX2012009388A (enExample)
RU (1) RU2566821C2 (enExample)
SG (3) SG183265A1 (enExample)
WO (1) WO2011100585A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740628C (en) * 2008-09-18 2018-05-01 Naurex, Inc. Nmda receptor modulators and uses thereof
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US9101612B2 (en) 2010-02-11 2015-08-11 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EP3514158B1 (en) 2013-01-29 2022-10-12 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA2899010A1 (en) * 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
EA031905B1 (ru) 2013-01-29 2019-03-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
CA2898774C (en) * 2013-01-29 2021-07-13 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2015065891A1 (en) * 2013-10-28 2015-05-07 Naurex, Inc. Nmda receptor modulators and prodrugs, salts, and uses thereof
KR20160144499A (ko) * 2014-04-25 2016-12-16 노렉스, 인크. 신경활성 펩타이드의 안정한 조성물
CN106661085A (zh) * 2014-06-23 2017-05-10 西北大学 治疗或改善偏头痛的方法
WO2016014982A1 (en) * 2014-07-24 2016-01-28 Naurex, Inc. N-methyl-d-aspartate receptor modulators and methods of making and using same
CA3001890A1 (en) 2015-10-14 2017-04-20 Bristol-Myers Squibb Company Selective nr2b antagonists
US10501451B2 (en) * 2015-10-14 2019-12-10 Bristol-Myers Squibb Company Selective NR2B antagonists
KR20180102052A (ko) * 2015-10-16 2018-09-14 노오쓰웨스턴 유니버시티 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
CN108779148A (zh) * 2016-02-01 2018-11-09 诺雷克斯股份有限公司 用于合成二吡咯烷肽化合物的方法
MX378566B (es) 2016-05-19 2025-03-11 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP2019527233A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用
EP3490990B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda modulators and methods of using same
KR102462288B1 (ko) 2016-08-01 2022-11-01 앱티닉스 인크. 스피로-락탐 및 비스-스피로-락탐 nmda 수용체 조정제 및 그의 용도
JP7032378B2 (ja) 2016-08-01 2022-03-08 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用
EP3490974B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
AU2019215058A1 (en) 2018-01-31 2020-09-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN112218866A (zh) * 2018-01-31 2021-01-12 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CN110003309B (zh) * 2019-04-09 2021-09-10 北京广为医药科技有限公司 调节nmda受体活性的化合物、其药物组合物及用途
AU2020323543A1 (en) * 2019-08-01 2022-02-24 Aptinyx Inc. Methods of treating disorders associated with elevated levels of antibodies that interact with the NMDA receptor
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
CN114957445B (zh) * 2022-05-31 2023-09-19 陕西脉元生物科技有限公司 一种nmdar nr1亚基、nmdar的突变体及其构建方法和应用
CN114957444B (zh) * 2022-05-31 2023-09-19 陕西脉元生物科技有限公司 一种nmdar的nr1亚基缺失突变体、突变体细胞及构建方法和应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683221A (en) 1986-01-09 1987-07-28 Scripps Clinic And Research Foundation Lymphocyte-activating polypeptides
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5350769A (en) 1990-10-30 1994-09-27 Ss Pharmaceutical Co., Ltd. Antiinflammatory gel preparation
JP3318622B2 (ja) 1992-05-27 2002-08-26 独立行政法人産業技術総合研究所 プロリルエンドペプチダーゼ阻害剤
FR2692268B1 (fr) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
SE9301667D0 (sv) 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
EP0914333B1 (en) 1996-06-07 2004-11-24 AstraZeneca AB Peptide derivatives
WO1998005782A1 (en) 1996-08-02 1998-02-12 Zymogenetics, Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (ja) 1996-09-27 2007-08-08 サントリー株式会社 新規アミノ酸ダイジハーベイン
EP0990051A1 (en) * 1997-07-07 2000-04-05 Florida State University Identification of molecular targets
US6897028B1 (en) 1997-07-07 2005-05-24 Florida State University Identification of molecular targets
AU1585999A (en) 1997-11-12 1999-05-31 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
US6902886B1 (en) 1998-11-06 2005-06-07 The Research Foundation Of State University Of New York Genetic assay for protein nuclear transport
WO2000028090A2 (en) 1998-11-12 2000-05-18 Nyxis, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2001036685A2 (en) 1999-11-17 2001-05-25 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
JP2003521247A (ja) 2000-02-01 2003-07-15 エージーワイ セラピューティクス インコーポレーテッド Ｎｍｄａ受容体のプロテインチロシンホスファターゼとの相互作用
WO2001096606A2 (en) 2000-06-14 2001-12-20 Nyxis Neurotherapies, Inc. Identification of genes and compounds for treatment of cancer
EP1296999A2 (en) 2000-06-22 2003-04-02 NYXIS NeuroTherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1186303A3 (en) 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
US20020142287A1 (en) 2000-12-14 2002-10-03 Hirotaka Yamamoto High throughput assay to detect inhibitors of the map kinase pathway
WO2002072005A2 (en) 2001-03-07 2002-09-19 University Of Utah Research Foundation Linear y-carboxyglutamate rich conotoxins
AU2002255705A1 (en) 2001-03-12 2002-09-24 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
US7863304B2 (en) 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
CA2449168A1 (en) 2001-05-31 2002-12-05 The Trustees Of Princeton University Iap binding peptides and assays for identifying compounds that bind iap
WO2003010540A1 (en) 2001-07-25 2003-02-06 Nyxis Neurotherapies, Inc. Method of identifying nmda-related agent
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US7544478B2 (en) 2003-08-08 2009-06-09 The Burnham Institute Method for screening for compounds that modulate P16 mediated regulation of NMDA receptors
US7662856B2 (en) 2003-08-29 2010-02-16 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
EP1945691A2 (en) * 2005-08-26 2008-07-23 Wisconsin Alumni Research Foundation Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
US8507439B2 (en) * 2005-08-29 2013-08-13 Angela Shashoua Neuroprotective and neurorestorative method and compositions
US20070208001A1 (en) 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
JP2010503677A (ja) 2006-09-15 2010-02-04 シェーリング コーポレイション 脂質代謝の障害を治療するためのアゼチジノン誘導体
CN101066945B (zh) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 一种合成3-位取代内酰胺类化合物的方法
CN101125817B (zh) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
WO2009039390A2 (en) 2007-09-20 2009-03-26 Naurex Inc. The development of glycobiology-based therapeutics for the treatment of brain tumors
CA2732091A1 (en) 2008-08-07 2010-02-11 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
CA2740628C (en) * 2008-09-18 2018-05-01 Naurex, Inc. Nmda receptor modulators and uses thereof
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
TW201028171A (en) 2008-12-15 2010-08-01 Calpis Co Ltd Peptides for inhibiting skin aging
US20120178695A1 (en) 2009-07-02 2012-07-12 Joseph Moskal Methods of treating neuropathic pain
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
EP3488856A1 (en) 2009-10-05 2019-05-29 Northwestern University Methods of treating depression and other related diseases
HUE029734T2 (en) * 2009-12-17 2017-03-28 Merck Sharp & Dohme Kinolin amide M1 receptor positive allosteric modulators
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US9101612B2 (en) * 2010-02-11 2015-08-11 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
KR20200043534A (ko) 2011-04-27 2020-04-27 노오쓰웨스턴 유니버시티 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
US8795919B2 (en) 2011-11-29 2014-08-05 Societe BIC & Sanyo Electric Co., Ltd. Fuel cell layer

Similar Documents

Publication Publication Date Title
JP2013519683A5 (enExample)
JP2015501783A5 (enExample)
JP2013532687A5 (enExample)
JP2013032389A5 (enExample)
JP2013530958A5 (enExample)
JP2015504870A5 (enExample)
JP2012107057A5 (enExample)
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
NO343929B3 (no) 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte
EP2881384A8 (en) Partially saturated nitrogen-containing heterocyclic compound
JP2011168603A5 (enExample)
ES2723277T3 (es) Una forma sólida de clorhidrato de (S)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
JP2012072162A5 (enExample)
JP2011105738A5 (enExample)
DOP2012000139A (es) Nuevos compuestos de espiropiperidina
JP2013525444A5 (enExample)
JP2015503422A5 (enExample)
JP2011518833A5 (enExample)
EP4643945A3 (en) Neuroactive steroids and methods of use thereof
EP2484673A3 (en) A process for the resolution of (R,S)-nicotine
ES2560676T3 (es) Combinación farmacéutica para el tratamiento del dolor
JP2012144574A5 (enExample)
JP2012519182A5 (enExample)
CL2014000395A1 (es) Compuestos derivados de piridazinona sustituida; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de la esquizofrenia, trastorno esquizoafectivo, trastornos cognitivos o dolor.
JP2014507477A5 (enExample)